Treating Hyperuricemia May Attenuate Kidney Function Decline in Some Patients with ADPKD

Among 365 patients with autosomal dominant polycystic kidney disease (ADPKD), those with hyperuricemia showed a faster annual decline in eGFR (-6.3% vs. -0.9% per year); however, after adjusting for various factors, serum uric acid was no longer associated with annual eGFR decline or the development of ESRD. Among 53 patients who received hypouricemic treatment, the annual eGFR decline was attenuated after hypouricemic treatment (pretreatment vs. posttreatment: -5.3 vs. 0.2 mL/min/1.73 m² per year). The BMC Nephrology findings suggest that hyperuricemia is not an independent factor for progression in ADPKD, but correcting it may attenuate kidney function decline in some patients.